Mona Makhamreh

Dr. Mona Makhamreh

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2023 in Clinical Genetics
Verified
Journal Article
Closed access
HAHuda B. Al‐Kouatly
Huda B. Al‐Kouatly
KSKavya Shivashankar
Kavya Shivashankar
MMMatthew H. Mossayebi
Matthew H. Mossayebi
MMMona Makhamreh
Mona Makhamreh
ECElizabeth Critchlow
Elizabeth Critchlow
SBSeth I. Berger
Seth I. Berger

29 December 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
MMMona Makhamreh
Mona Makhamreh
KSKavya Shivashankar
Kavya Shivashankar
SASarah Araji
Sarah Araji
ECElizabeth Critchlow
Elizabeth Critchlow
BOBarbara M. O'BRien
Barbara M. O'BRien
HAHuda B. Al‐Kouatly
Huda B. Al‐Kouatly

13 October 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMona Makhamreh
Mona Makhamreh
MCMei Ling Chong
Mei Ling Chong
Ignatia B Van den VeyverIgnatia B Van den Veyver
Ignatia B Van den Veyver
Advancements in genomic technologies have transformed prenatal genetic testing, offering more accurate, comprehensive, and noninvasive approaches to reproductive care. This review provides an in-depth overview of current methodologies and emerging innovations, including expanded carrier screening (ECS), cell-free DNA (cfDNA) testing, chromosomal microarray analysis (CMA), and sequencing-based diagnostics. We highlight how next-generation sequencing (NGS) technologies have revolutionized carrier screening and fetal genome analysis, enabling detection of a broad spectrum of genetic conditions. The clinical implementation of cfDNA has expanded from common aneuploidies to include copy number variants (CNVs), and single-gene disorders. Diagnostic testing has similarly evolved, with genome sequencing outperforming traditional CMA and exome sequencing through its ability to detect both sequence and structural variants in a single assay. Emerging tools such as optical genome mapping, RNA sequencing, and long-read sequencing further enhance diagnostic yield and variant interpretation. This review summarizes major technological advancements, assesses their clinical utility and limitations, and outlines future directions in prenatal genomics.

22 November 2019 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MMMona Makhamreh
Mona Makhamreh
SKStephanie L. Kass
Stephanie L. Kass
MRMelissa L. Russo
Melissa L. Russo
HAHoma Ahmadzia
Homa Ahmadzia
HAHuda B. Al-Kouatly
Huda B. Al-Kouatly
Objective von Willebrand disease (VWD) is a hereditary bleeding disorder. Type 3 VWD is the most severe and rare phenotype that presents many challenges for management of pregnant women. The aim of this study was to review the maternal characteristics and complications in pregnant women with Type 3 VWD.Study Design A systematic literature search was performed to include all publications that address Type 3 VWD in pregnancy.Results Thirteen studies met the inclusion criteria. There were 28 pregnancies with Type 3 VWD in 17 women. All were diagnosed with Type 3 VWD prior to pregnancy. Concentrate treatment was administered before delivery for 19 pregnancies and postpartum for 26 pregnancies. Eight pregnancies required blood products postpartum. Primary postpartum hemorrhage (PPH) was reported in 48% (10/21) and secondary PPH was reported in 56% (5/9). Secondary PPH occurred between 7 and 22 days. No study reported hysterectomies, intensive care unit admissions, or maternal mortality. All 28 pregnancies resulted in 28 live births at term.Conclusion Our review highlights the maternal outcomes in patients with Type 3 VWD and the different approaches in management during pregnancy and delivery. Despite prior knowledge of this bleeding disorder, PPH was still a significant complication.

27 October 2023 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
ECElizabeth Critchlow
Elizabeth Critchlow
SWSascha Wodoslawsky
Sascha Wodoslawsky
MMMona Makhamreh
Mona Makhamreh
SRStephanie M. Rice
Stephanie M. Rice
OTOzhan Turan
Ozhan Turan
HAHuda B. Al‐Kouatly
Huda B. Al‐Kouatly

19 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMona Makhamreh
Mona Makhamreh
MCMei Ling Chong
Mei Ling Chong
Ignatia B Van den VeyverIgnatia B Van den Veyver
Ignatia B Van den Veyver
Advancements in genomic technologies have transformed prenatal genetic testing, offering more accurate, comprehensive, and noninvasive approaches to reproductive care. This review provides an in-depth overview of current methodologies and emerging innovations, including expanded carrier screening (ECS), cell-free DNA (cfDNA) testing, chromosomal microarray analysis (CMA), and sequencing-based diagnostics. We highlight how next-generation sequencing (NGS) technologies have revolutionized carrier screening and fetal genome analysis, enabling detection of a broad spectrum of genetic conditions. The clinical implementation of cfDNA has expanded from common aneuploidies to include copy number variants (CNVs), and single-gene disorders. Diagnostic testing has similarly evolved, with genome sequencing outperforming traditional CMA and exome sequencing through its ability to detect both sequence and structural variants in a single assay. Emerging tools such as optical genome mapping, RNA sequencing, and long-read sequencing further enhance diagnostic yield and variant interpretation. This review summarizes major technological advancements, assesses their clinical utility and limitations, and outlines future directions in prenatal genomics.